About this market
Increased incidence of travel-related diseases is expected to drive the market growth. Traveling is often associated with higher health risks especially regarding infectious diseases. Thus, the rising incidence of travel related diseases will lead to more investments in the global travel vaccines market for the development of more effective vaccines. analysts have predicted that the travel vaccines market will register a CAGR of almost 10% by 2022.
Market Overview
Increase in global travel and migration
With the rise in traveling over the past few years has resulted in the spread of pathogens and disease-causing vectors worldwide. The increase in travel and migration offers huge opportunities to the manufacturers to invest in the R&D of new and more effective vaccines.
High cost of travel vaccinations
Travel clinics offer vaccinations at a slightly higher price and new vaccines are usually more expensive.
For the detailed list of factors that will drive and challenge the growth of the travel vaccines market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Sanofi and Valneva the competitive environment is quite intense. Factors such as the increased incidence of travel-related diseases and the increase in global travel and migration, will provide considerable growth opportunities to travel vaccines manufactures. GlaxoSmithKline, Pfizer, Sanofi, and Valneva are some of the major companies covered in this report.